Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. announced a change in equity holdings, with shareholders holding more than 5% of the company’s shares experiencing a decrease from 9.73% to 8.96%. This change does not breach any commitments or trigger mandatory tender offer obligations, indicating a stable transition in shareholder structure without immediate impact on the company’s strategic plans.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$11.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biotechnology company based in China, specializing in the development and commercialization of innovative therapies. The company is focused on the biopharmaceutical industry, providing advanced medical solutions to address unmet clinical needs.
Average Trading Volume: 3,664,542
Technical Sentiment Signal: Buy
Current Market Cap: HK$32.17B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.